Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Precision BioSciences, Inc. (NASDAQ:DTIL) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $32.25.

A number of brokerages have issued reports on DTIL. Jefferies Financial Group reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Precision BioSciences in a research report on Friday, March 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research report on Wednesday, May 27th. Wall Street Zen raised shares of Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings raised shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Finally, JonesTrading reissued a “buy” rating and set a $30.00 target price on shares of Precision BioSciences in a research report on Friday, April 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its position in shares of Precision BioSciences by 167.6% during the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock valued at $151,000 after acquiring an additional 17,172 shares during the period. Quantinno Capital Management LP bought a new position in shares of Precision BioSciences during the 1st quarter valued at approximately $104,000. Octagon Capital Advisors LP grew its position in shares of Precision BioSciences by 16.6% during the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock valued at $12,302,000 after acquiring an additional 318,737 shares during the period. Affinity Asset Advisors LLC bought a new position in shares of Precision BioSciences during the 1st quarter valued at approximately $3,289,000. Finally, XTX Topco Ltd bought a new position in shares of Precision BioSciences during the 4th quarter valued at approximately $149,000. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Trading Down 1.1%

Shares of DTIL stock opened at $6.10 on Tuesday. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $8.82. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. The company has a 50-day simple moving average of $7.05 and a two-hundred day simple moving average of $5.48. The company has a market capitalization of $157.38 million, a price-to-earnings ratio of -1.66 and a beta of 1.30.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.The firm had revenue of $10.84 million during the quarter, compared to the consensus estimate of $4.05 million. Research analysts anticipate that Precision BioSciences will post -2.21 EPS for the current fiscal year.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.